147 related articles for article (PubMed ID: 15179666)
41. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.
Gourzis P; Polychronopoulos P; Papapetropoulos S; Assimakopoulos K; Argyriou AA; Beratis S
Clin Neuropharmacol; 2005; 28(4):195-6. PubMed ID: 16062102
[TBL] [Abstract][Full Text] [Related]
42. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
43. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
44. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
45. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
46. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Miller EA; Leslie DL; Rosenheck RA
J Nerv Ment Dis; 2005 Jun; 193(6):387-95. PubMed ID: 15920379
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
48. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Citrome L; Volavka J
Postgrad Med; 2004 Oct; 116(4):49-51, 55-9, 63. PubMed ID: 15510593
[TBL] [Abstract][Full Text] [Related]
49. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
50. Atypical antipsychotics and glucose homeostasis.
Bergman RN; Ader M
J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
[TBL] [Abstract][Full Text] [Related]
51. Atypical antipsychotics and weight gain--a systematic review.
Taylor DM; McAskill R
Acta Psychiatr Scand; 2000 Jun; 101(6):416-32. PubMed ID: 10868465
[TBL] [Abstract][Full Text] [Related]
52. Glucose intolerance with atypical antipsychotics.
Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
[TBL] [Abstract][Full Text] [Related]
53. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Park Y; Hernandez-Diaz S; Bateman BT; Cohen JM; Desai RJ; Patorno E; Glynn RJ; Cohen LS; Mogun H; Huybrechts KF
Am J Psychiatry; 2018 Jun; 175(6):564-574. PubMed ID: 29730938
[TBL] [Abstract][Full Text] [Related]
54. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
55. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.
Barbee JG; Conrad EJ; Jamhour NJ
J Clin Psychiatry; 2004 Jul; 65(7):975-81. PubMed ID: 15291687
[TBL] [Abstract][Full Text] [Related]
56. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.
Gianfrancesco F; Pesa J; Wang RH; Nasrallah H
Am J Health Syst Pharm; 2006 Mar; 63(5):431-41. PubMed ID: 16484517
[TBL] [Abstract][Full Text] [Related]
57. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
58. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
59. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
Peritogiannis V; Tsouli S
J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
[TBL] [Abstract][Full Text] [Related]
60. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
